<DOC>
	<DOC>NCT00530309</DOC>
	<brief_summary>A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus</brief_summary>
	<brief_title>Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Type 2 diabetes mellitus diagnosed at least 3 months with FPG level &lt;=240mg/dL and HbA1c between 6.5% and 10% inclusive. Must be diet controlled OR taking a single oral antidiabetic agent (other than thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to the study. Must have a BMI:&lt;=35kg/m2, 20 to 70 years of age inclusive. Woman must be of nonchildbearing potential. Exclusion criteria: Positive test result for either syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, or HTLV1 antibody. Clinically significant hepatic enzyme elevation. History of metabolic disease other than T2DM. Previous use of insulin as a treatment for diabetes within 3 months. History of severe gastrointestinal disease. Clinically significant cardiovascular disease. Significant renal disease as defined by screening lab test. History of drug (including albumin or albumin containing agents) allergy. History of alcohol or drug abuse. Donation of blood in excess of 400mL within previous 4 months. Previously received any GLP1 mimetic or any other albumincontaining products.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>type 2 diabeted mellitus</keyword>
	<keyword>safety</keyword>
	<keyword>GSK716155</keyword>
	<keyword>GLP-1 receptor agonist</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>